New hope for advanced stomach cancer: Triple-Drug combo tested in major trial
NCT ID NCT07315750
First seen Jan 06, 2026 · Last updated May 24, 2026 · Updated 21 times
Summary
This study tests a new combination of three drugs (disitamab vedotin, trastuzumab, and tislelizumab) against standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has high levels of a protein called HER2. The goal is to see if the new combo helps people live longer without their cancer getting worse. About 555 adults who have not had prior treatment for advanced disease will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, BJ-Beijing, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.